Isolation and large-scale expansion of bone marrow-derived mesenchymal stem cells with serum-free media under GMP-compliance

Cytotherapy ◽  
2014 ◽  
Vol 16 (4) ◽  
pp. S111 ◽  
Author(s):  
S.H. Mei ◽  
M. Salkhordeh ◽  
F. Xue ◽  
J. Zhang ◽  
I. Watpool ◽  
...  
2008 ◽  
Vol 14 (3) ◽  
pp. 185-196 ◽  
Author(s):  
Katharina Schallmoser ◽  
Eva Rohde ◽  
Andreas Reinisch ◽  
Christina Bartmann ◽  
Daniela Thaler ◽  
...  

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Maria C. Naskou ◽  
Scarlett M. Sumner ◽  
Anna Chocallo ◽  
Hannah Kemelmakher ◽  
Merrilee Thoresen ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-21 ◽  
Author(s):  
Sunghoon Jung ◽  
Krishna M. Panchalingam ◽  
Lawrence Rosenberg ◽  
Leo A. Behie

Human mesenchymal stem cells (hMSCs) are presently being evaluated for their therapeutic potential in clinical studies to treat various diseases, disorders, and injuries. To date, early-phase studies have indicated that the use of both autologous and allogeneic hMSCs appear to be safe; however, efficacy has not been demonstrated in recent late-stage clinical trials. Optimized cell bioprocessing protocols may enhance the efficacy as well as safety of hMSC therapeutics. Classical media used for generating hMSCs are typically supplemented with ill-defined supplements such as fetal bovine serum (FBS) or human-sourced alternatives. Ideally, culture media are desired to have well-defined serum-free formulations that support the efficient production of hMSCs while maintaining their therapeutic and differentiation capacity. Towards this objective, we review here current cell culture media for hMSCs and discuss medium development strategies.


2020 ◽  
Vol 2020 ◽  
pp. 1-17 ◽  
Author(s):  
Muhammad Najib Fathi Bin Hassan ◽  
Muhammad Dain Yazid ◽  
Mohd Heikal Mohd Yunus ◽  
Shiplu Roy Chowdhury ◽  
Yogeswaran Lokanathan ◽  
...  

Mesenchymal stem cells (MSCs) are multipotent stem cells with strong immunosuppressive property that renders them an attractive source of cells for cell therapy. MSCs have been studied in multiple clinical trials to treat liver diseases, peripheral nerve damage, graft-versus-host disease, autoimmune diseases, diabetes mellitus, and cardiovascular damage. Millions to hundred millions of MSCs are required per patient depending on the disease, route of administration, frequency of administration, and patient body weight. Multiple large-scale cell expansion strategies have been described in the literature to fetch the cell quantity required for the therapy. In this review, bioprocessing strategies for large-scale expansion of MSCs were systematically reviewed and discussed. The literature search in Medline and Scopus databases identified 26 articles that met the inclusion criteria and were included in this review. These articles described the large-scale expansion of 7 different sources of MSCs using 4 different bioprocessing strategies, i.e., bioreactor, spinner flask, roller bottle, and multilayered flask. The bioreactor, spinner flask, and multilayered flask were more commonly used to upscale the MSCs compared to the roller bottle. Generally, a higher expansion ratio was achieved with the bioreactor and multilayered flask. Importantly, regardless of the bioprocessing strategies, the expanded MSCs were able to maintain its phenotype and potency. In summary, the bioreactor, spinner flask, roller bottle, and multilayered flask can be used for large-scale expansion of MSCs without compromising the cell quality.


2010 ◽  
Vol 69 (10) ◽  
pp. 1880-1885 ◽  
Author(s):  
J. R. Lamas ◽  
L. Rodriguez-Rodriguez ◽  
A. G. Vigo ◽  
R. Alvarez-Lafuente ◽  
P. Lopez-Romero ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document